CXCL9 and breast carcinoma: In a previous study, Lu et al. demonstrated that guadecitabine, a next generation DNA methyltransferase inhibitor (DNMTi), significantly up-regulated the expression of CXCL9/10/11 as well as major histocompatibility class I in breast cancer cells [40].